Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
J Eur Acad Dermatol Venereol
; 31(10): 1638-1640, 2017 Oct.
Article
em En
| MEDLINE
| ID: mdl-28401596
ABSTRACT
BACKGROUND:
The combination treatment with BRAF and MEK inhibitors is amongst the current standard of care for stage IIIC/IV BRAF-mutated melanoma. However, therapeutic options are limited once patients have progressed upon both targeted and immunotherapy.OBJECTIVE:
To investigate whether retreatment with BRAF and MEK inhibitor combination is an option for patients with metastatic BRAF-mutated melanoma upon previous progression on kinase inhibitors.METHODS:
Two patients with metastatic BRAF-mutated melanoma were rechallenged with BRAF and MEK inhibitor combination after progression on targeted therapy and subsequent immunotherapy with anti-CTLA-4 and anti-PD-1 antibodies.RESULTS:
Both patients responded to retreatment. Responses were limited to a few months and associated with a considerable increase in quality of life.CONCLUSION:
Retreatment with BRAF and MEK inhibitors may present a feasible treatment option upon progression on both kinase inhibitors and immunotherapy, and should be considered when all other treatment options have been exhausted.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
MAP Quinase Quinase Quinases
/
Proteínas Proto-Oncogênicas B-raf
/
Inibidores de Proteínas Quinases
/
Melanoma
/
Metástase Neoplásica
/
Antineoplásicos
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Eur Acad Dermatol Venereol
Assunto da revista:
DERMATOLOGIA
/
DOENCAS SEXUALMENTE TRANSMISSIVEIS
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Suíça